

Claims

- 1) Use of adeno-associated viruses for lowering the radiotherapy-induced or chemotherapy-induced resistance in patients who suffer from a cancer which is to be treated by radiotherapy or chemotherapy.
5
- 2) Use according to claim 1, wherein the adeno-associated viruses are used in a dose of 10^9 - 10^{10} AAV particles/kg body weight.
- 3) Use according to any of claims 1 to 2, wherein the adeno-associated virus is adeno-associated virus 2 (AAV-2).
10
- 4) Use according to any of claims 1 to 3, wherein the cancer to be treated by radiotherapy or chemotherapy is a colon cancer, pancreatic carcinoma or brain tumor or small cell lung carcinoma.
15
- 5) Use according to any of claims 1 to 4, wherein the use is made intravenously, cutaneously, orally or intratumorally.
- 6) Use according to any of claims 1 to 5, wherein the use is made before, after or
20 simultaneously with a chemotherapy or radiotherapy.
- 7) A pharmaceutical composition containing a chemotherapeutic agent and adeno-

associated viruses.

8.) The pharmaceutical composition according to claim 7, wherein the chemotherapeutic agent is cisplatin and/or etoposide.

5

9) The pharmaceutical composition according to claim 7 or 8, wherein it is an injection or infusion solution, an aerosol spray or an ointment.